UKI2S Portfolio Company Marketing Seminar

More From the Blog

CellCentric raises $26m for new late-state prostate cancer drug

UKI2S biotech company CellCentric, University of Cambridge spinout, has raised $26m to fund clinical...

read more

Funding New Spinouts & Backing an Industry Leader

We work closely with our partner laboratories to identify commercial opportunities arising from their...

read more